1. Home
  2. DRTS vs CERS Comparison

DRTS vs CERS Comparison

Compare DRTS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$7.25

Market Cap

546.5M

Sector

Health Care

ML Signal

HOLD

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$1.80

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRTS
CERS
Founded
2015
1991
Country
Israel
United States
Employees
125
N/A
Industry
Medical/Dental Instruments
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
546.5M
276.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
DRTS
CERS
Price
$7.25
$1.80
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
269.7K
2.0M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.27
EPS
N/A
N/A
Revenue
N/A
$51,326,000.00
Revenue This Year
N/A
$20.00
Revenue Next Year
$1,055.39
$9.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.68
52 Week Low
$2.30
$1.12
52 Week High
$8.60
$2.96

Technical Indicators

Market Signals
Indicator
DRTS
CERS
Relative Strength Index (RSI) 52.24 37.19
Support Level $6.51 $1.37
Resistance Level $7.77 $2.26
Average True Range (ATR) 0.52 0.16
MACD -0.05 -0.06
Stochastic Oscillator 41.74 17.45

Price Performance

Historical Comparison
DRTS
CERS

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: